Toggle Health Problems and D

Lung cancer treated by Vitamin D (1200 IU early stage) – RCT July 2018

Vitamin D supplementation and survival of patients with non-small-cell lung cancer: A randomized, double-blind, placebo-controlled trial.

Clin Cancer Res. 2018 Jul 17. pii: clincanres.0483.2018. doi: 10.1158/1078-0432.CCR-18-0483. [Epub ahead of print]


1200 IU for 8 years
Relapse-Free-Survival for those starting with < 20 ng of vitamin D

It is amazing that such a small amount of Vitamin D would help.
Suspect that the Japanese patients were very light-weight
Would need larger doses for standard-weight adults
Larger doses would likely also provide more benefits

Releapse-Free-Survival vs genes (not Vitamin D)


Vitamin D both prevents and treats many cancers
Cancer category starts with the following

Cancers get less Vitamin D when there is a poor Vitamin D Receptor

PDF is available free at Sci-Hub  10.1158/1078-0432.CCR-18-0483

Akiba T1, Morikawa T2, Odaka M2, Nakada T2, Kamiya N3, Yamashita M2, Yabe M2, Inagaki T2, Asano H2, Mori S2, Tsukamoto Y2, Urashima M4.
1 Thoracic Surgery, Jikei University School of Medicine University Hospital.
2 Thoracic Surgery, Tokyo Jikei University of Medicine.
3 Thoracic Surgery, Kitasato University Kitasato institute hospital.
4 Molecular Epidemiology, Jikei University School of Medicine urashima at jikei.ac.jp.

Higher serum 25-hydroxyvitamin D (25(OH)D) levels are reportedly associated with better survival in early-stage non-small-cell lung cancer (NSCLC). Therefore, whether vitamin D supplementation can improve the prognosis of NSCLC patients was examined (UMIN000001869). &#10; Experimental

Design: A randomized, double-blind trial comparing vitamin D supplements (1,200 IU/day) with placebo for 1 year after operation was conducted. The primary and secondary outcomes were relapse-free survival (RFS) and overall survival (OS), respectively. Pre-specified subgroup analyses were performed with stratification by stage (early vs. advanced), pathology (adenocarcinoma vs. others), and 25(OH)D levels (<20 ng/ml vs. high, ≥20 ng/ml). Polymorphisms of vitamin D receptor (VDR) and vitamin D binding protein (DBP) and survival were also examined. &#10;

Results: NSCLC patients (n=155) were randomly assigned to receive vitamin D (n=77) or placebo (n=78) and followed for a median of 3.3 years. Relapse and death occurred in 40 (28%) and 24 (17%) patients, respectively. In the total study population, no significant difference in either RFS or OS was seen with vitamin D compared to the placebo group.
However, by restricting the analysis to the subgroup with early-stage adenocarcinoma with low 25(OH)D, the vitamin D group showed significantly better

  • 5-year RFS (86% vs. 58%, P=0.04) and
  • OS (92% vs. 56%, P=0.02)

than the placebo group. Among the examined polymorphisms, DBP1 (rs7041) TT and CDX2 (rs11568820) AA/AG genotypes were markers of better prognosis, even with multivariate adjustment. &#10;
Conclusions: In NSCLC patients, vitamin D supplementation may improve survival of early-stage lung adenocarcinoma patients with lower 25(OH)D levels.

Created by admin. Last Modification: Tuesday September 4, 2018 15:13:59 GMT-0000 by admin. (Version 10)

Attached files

ID Name Comment Uploaded Size Downloads
10482 LC relapse free survival vs gene.jpg admin 04 Sep, 2018 15:01 16.12 Kb 655
10481 LC relapse free survival.jpg admin 04 Sep, 2018 14:57 13.36 Kb 613